Targeted therapy before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive invasive breast cancer that has not spread far (stage II to IIIA).
- Your tumor is at least 2 cm in size or has spread to nearby lymph nodes.
- You are in good general health (able to care for yourself and up and about).
- Your heart function (LVEF) is normal (50% or higher).
- You are not pregnant or breastfeeding and are at least 18 years old.
- Your kidney, liver, and bone marrow function are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.